Elsevier

Vaccine

Volume 30, Issue 50, 26 November 2012, Pages 7214-7220
Vaccine

Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines

https://doi.org/10.1016/j.vaccine.2012.10.022Get rights and content

Abstract

Helicobacter pylori is an important pathogen of the human stomach, and the development of a protective vaccine has been an enticing goal for many years. The H. pylori antioxidant enzymes superoxide dismutase (SOD) and catalase (KatA) have been shown to be protective as vaccine antigens in mice, demonstrating that the organism's antioxidant enzyme system is a fruitful target for vaccine development. The research described here demonstrates that an additional antioxidant enzyme, thiolperoxidase (Tpx), is effective as a prophylactic vaccine antigen via both systemic and mucosal routes. The functional relationship between SOD, KatA and Tpx also provided an opportunity to investigate synergistic or additive effects when the three antigens were used in combination. Although the antigens still provided equivalent protection when administered in combination, no additional protection was observed. Moreover a decrease in antibody titres to the individual antigens was observed when delivered in combination via the nasal route, though not when injected subcutaneously. The findings of this paper demonstrate that the antioxidant system of H. pylori presents a particularly rich resource for vaccine development.

Highlights

Helicobacter pylori thiolperoxidase was a protective systemic vaccine antigen. ► H. pylori thiolperoxidase was a protective mucosal vaccine antigen. ► Vaccinating with a combination of antioxidant enzymes did not improve protection. ► The immunogenicity of individual antigens was reduced when given in combination via the nasal route.

Introduction

The development of an effective vaccine against Helicobacter pylori has been an enticing prospect for many years. H. pylori, a Gram-negative pathogenic bacterium of the human stomach, is now understood to be the leading cause of gastritis [1]; the chronic inflammation elicited by its colonisation is directly implicated in the development of gastric adenocarcinoma [2] and gastric MALT (mucosal-associated lymphoid tissue) lymphoma [3]. Estimates suggest that a hypothetical infant vaccination program with a preventative efficacy of 80% would be a highly cost-effective method of control, and even a vaccine with an efficacy as low as 20% may still prove cost-effective in the long-term due to the ability to prevent gastric neoplasia [4].

Vaccine development is driven in large part by the discovery of antigens that induce an effective immune response. Several H. pylori proteins have already been reported as effective vaccine antigens. Urease is the most extensively studied of these antigens [5], [6], [7], [8], [9], [10], but a range of others have been assessed, including VacA cytotoxin [11], heat-shock proteins [12], HpaA [13], NapA [14] and CagA [11]. Each of these antigens, when combined with a suitable adjuvant, is capable of reducing H. pylori colonisation when administered to mice, proving that it is possible to induce a protective effect through vaccination. However, the vaccine formulations described are yet to generate reproducible sterilising immunity.

The H. pylori enzyme thiolperoxidase (Tpx) is a thioredoxin-dependent peroxiredoxin with non-specific peroxidase activity, and is reported to be involved in defence against oxidative damage [15]. The enzyme fulfils many desirable attributes of protective vaccine antigens. It is important for survival in vivo, with Tpx-deficient mutant strains demonstrating increased sensitivity to oxidative stress and failure to colonise mice [16]. Furthermore, the enzyme presents at the surface of the organism [17] and in outer membrane vesicles [18], and is abundant within the proteome [19]. This paper explores the potential of Tpx as a mucosal and systemic vaccine antigen.

In addition, the previous characterisation of two other H. pylori antioxidant enzymes as partially protective vaccine antigens – catalase (KatA) and superoxide dismutase (SOD) [20], [21] – provided the opportunity to assess these antigens in a combination vaccine with Tpx. The functional relationship between these three antigens suggested a potential for synergistic vaccine activity through impairment of different branches of the antioxidant system. As defects in multiple antioxidant enzymes have been shown to cause additional sensitivity to oxidative stress [22], it was proposed that using these antigens in combination may increase the efficacy of the vaccine.

Section snippets

H. pylori culture

H. pylori strains SS1 [23] and J99 [24] were grown on horse blood agar plates (Blood Agar Base No. 2, 2.5 μg/mL amphotericin B (Sigma–Aldrich, Castle Hill, Australia) and Skirrow's Selective Supplements (Oxoid, Basingstoke, UK) and 5% horse blood (Biolab, Mulgrave, Australia) in an anaerobic jar with a microaerophilic gas generating kit (Oxoid) for 2 days at 37 °C. For infection experiments and extraction of genomic DNA, bacteria were subcultured into brain heart infusion broth (BHI; Oxoid)

Tpx is a protective vaccine antigen when delivered via subcutaneous and nasal routes

Evaluation of Tpx as a vaccine antigen was first assessed by subcutaneous immunisation. In addition to Tpx, both SOD and KatA have been demonstrated to be protective antigens against H. pylori [20], [21]. Moreover, as these enzymes are integral components of the H. pylori anti-oxidative enzyme defence system, we hypothesised that a combined vaccination comprised of these three antigens (Tri-Vac) may produce a synergistic protective effect by generating immune responses to different components

Discussion

Antioxidant enzymes are an important defence mechanism for H. pylori, providing vital protection against the damaging effects of reactive oxygen species (ROS). These toxic compounds are generated by a variety of sources in response to infection. Neutrophils and other phagocytes produce ROS during gastritis [34], [35], and gastric epithelial cells have also been shown to generate ROS on exposure to H. pylori [36]. Without a well-developed antioxidant system, H. pylori is susceptible to

Acknowledgements

This work was supported by the Victorian Government's Operational Infrastructure Support Program and by Australian Research Council (ARC) Linkage Project grant LP0560720. PS is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. The funders had no role in the experiments performed, or the preparation of this manuscript.

Contributors: AS, ALE, GZN, YTC and LSO were involved in acquisition of the data. AS, ALE, SE and PS conceived and

References (47)

  • D.W. Cleveland et al.

    Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis

    J Biol Chem

    (1977)
  • H. Nielsen et al.

    Activation of human phagocyte oxidative metabolism by Helicobacter pylori

    Gastroenterology

    (1992)
  • A.A. O’Riordan et al.

    Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine

    Vaccine

    (2012)
  • P. Malfertheiner et al.

    Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study

    Gastroenterology

    (2008)
  • T.G. Blanchard et al.

    Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice

    Cell Immunol

    (1999)
  • J. Labenz et al.

    Evidence for the essential role of Helicobacter pylori in gastric ulcer disease

    Gut

    (1994)
  • N. Uemura et al.

    Helicobacter pylori infection and the development of gastric cancer

    N Engl J Med

    (2001)
  • M.F. Rupnow et al.

    Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States

    J Infect Dis

    (2009)
  • R.L. Ferrero et al.

    Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection

    Infect Immun

    (1994)
  • T.H. Ermak et al.

    Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses

    J Exp Med

    (1998)
  • C.K. Lee et al.

    Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis

    J Infect Dis

    (1995)
  • X.L. Yang et al.

    Oral immunization of mice with vaccine of attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit

    Biomed Environ Sci

    (2005)
  • P. Ghiara et al.

    Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection

    Infect Immun

    (1997)
  • Cited by (22)

    • A survey on chimeric UreB<inf>229-561</inf>-HpaA protein targeting Helicobacter pylori: Computational and in vitro urease activity valuation

      2018, Computational Biology and Chemistry
      Citation Excerpt :

      The initial challenges for vaccine development against H. pylori were primarily focused on monovalent recombinant vaccines. Meanwhile, paralleled to single antigens, multi subunit vaccines have been assessed to display vaccine-induced protection against the infection, such as omp22 plus HpaA, SOD plus catalase, GreES plus UreB, UreA plus HpaA, Tpx plus catalase, gGT plus UreB, and HspA plus gGT (Huang et al., 2013; Vermoote et al., 2013; Stent et al., 2012; Ferrero et al., 1995; Zhang et al., 2015). Moreover, construction of chimeric fusion epitopes were favorable strategies for development of vaccine candidate based on Salmonella expression system (Liu et al., 2011).

    • Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant

      2014, Vaccine
      Citation Excerpt :

      Animal experimentation was performed under institutional guidelines and with approval from the University of Melbourne Animal Ethics Committee. Groups of age-matched, female C57BL/6 mice were dosed either subcutaneously or nasally as previously described [22,23]. Anti-H.

    • Key host-pathogen interactions for designing novel interventions against Helicobacter pylori

      2013, Trends in Microbiology
      Citation Excerpt :

      Perhaps one means to attain this goal would be to establish a prioritized panel of antigens that can enhance a protective immune response and result in the elimination of infection. Recently, H. pylori superoxide dismutase (HpSOD) and thiolperoxidase (Hptpx) were demonstrated to be additional antigens capable of inducing immunity and reducing H. pylori burdens when codelivered with an appropriate adjuvant [50,51]. Indeed, HpSOD and Hptpx represent attractive vaccine candidates for two major reasons – they are expressed on the surface of the bacteria [52–54], therefore increasing access to the antigen by the immune system, and they are also essential for H. pylori survival in vivo [55,56] – where they protect against reactive oxygen species produced both through internal metabolic processes and by neutrophils and macrophages (Figure 1E,F).

    View all citing articles on Scopus
    View full text